Adicet Bio, Inc. ACET
Adicet Bio, Inc. (Nasdaq: ACET) is an immunology/inflammation drug developer. Its lead program, prula-cel (prulacabtagene leucel, ADI-001), is in Phase 1 for autoimmune diseases (lupus nephritis, SLE, SSc, AAV, IIM, SPS). Its next catalyst on record is prula-cel: Potential pivotal program start in LN, subject to regulatory clearance (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: prula-cel — Potential pivotal program start in LN, subject to regulatory clearance (H2 2026). 15 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| prula-cel (CD20 CAR gamma delta T) - LN/SLE/SSc/AAV/IIM/SPS | autoimmune diseases | cell therapy | Phase 1 |
| prula-cel - rheumatoid arthritis | treatment-refractory rheumatoid arthritis | cell therapy | Phase 1 |
| ADI-212 (PSMA CAR gamma delta T) | metastatic castration-resistant prostate cancer | cell therapy | Pre-clinical |
| In vivo CAR-T platform/pipeline | hematologic malignancies and solid tumors | cell therapy | Pre-clinical |
Recent results and decisions
- Sep 28, 2026positive Phase 1 prula-cel in SLE/LN (22 evaluable): at 12 months 50% of LN patients had complete renal response and 54% achieved DORIS remission, no CRS above Grade 2, no ICANS or IEC-HS.
At the 12-month mark, 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission.
Filing - Aug 28, 2026positive Prula-cel Phase 1 study showed 54% DORIS remission and 50% complete renal response at 12 months in SLE/LN patients with favorable safety profile.
At the 12-month mark, 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.